Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating lung cancer

A composition and medicine technology, applied in the field of pharmaceutical compositions for the treatment of lung cancer, can solve the problems of inability to obtain a large amount of separation, low content and the like

Inactive Publication Date: 2019-08-13
XIAN GIANT BIOGENE TECH CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The content of ginsenoside Rk3 in natural ginseng is extremely small and cannot be isolated in large quantities
At present, there is no manufacturer that can prepare large quantities of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating lung cancer
  • Pharmaceutical composition for treating lung cancer
  • Pharmaceutical composition for treating lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Inhibitory effects of ginsenoside Rk3 and gefitinib alone and in combination for 48 hours on the proliferation of lung cancer NCI-H460 cells

[0020] Lung cancer NCI-H460 cells were inoculated in a sterile 96-well plate, and after culturing for 48 hours, 0-100 µM ginsenoside Rk3, or 0-50 µM gefitinib, 0-100 µM ginsenoside Rk3 and 0 Coadministration with ~50 µM gefitinib. An equal volume of 1640 culture solution was added to the control group, and 5 replicate wells were set for each concentration. After culturing for 48 h, 5 μg / mL MTT was added to each well, and the culture was continued for 4 h. Add 150 µL DMSO and shake slowly for 10 min to dissolve the blue-purple crystal Formazan formed. Detect the absorbance A value corresponding to each well at 570 nm, and use the following formula to calculate the cell inhibition rate:

[0021] Inhibition rate = (1-average A value of drug administration group / average A value of control group) × 100%

[0022] Depend on figure ...

Embodiment 2

[0024] Inhibitory effects of ginsenoside Rk3 and gefitinib alone and in combination for 48 hours on the proliferation of lung cancer A549 cells

[0025] Lung cancer A549 cells were inoculated in a sterile 96-well plate, and after culturing for 48 hours, 0-100 µM ginsenoside Rk3, or 0-50 µM gefitinib, 0-100 µM ginsenoside Rk3 and 0-50 µM Combination with gefitinib. An equal volume of 1640 culture solution was added to the control group, and 5 replicate wells were set for each concentration. After culturing for 48 h, 5 μg / mL MTT was added to each well, and the culture was continued for 4 h. Add 150 µL DMSO and shake slowly for 10 min to dissolve the blue-purple crystal Formazan formed. Detect the absorbance A value corresponding to each well at 570 nm, and use the following formula to calculate the cell inhibition rate:

[0026] Inhibition rate = (1-average A value of drug administration group / average A value of control group) × 100%

[0027] Depend on figure 2 It can be s...

Embodiment 3

[0029] Effects of ginsenoside Rk3 and gefitinib alone and in combination on apoptosis of lung cancer NCI-H460 cells

[0030] Lung cancer NCI-H460 cells were inoculated in a sterile 6-well plate, and after culturing for 24 hours, 0-50 µM ginsenoside Rk3, or 0-25 µM gefitinib, 0-50 µM ginsenoside Rk3 and 0 Coadministration with ~25 µM gefitinib. An equal volume of 1640 culture solution was added to the control group, and 5 replicate wells were set for each concentration. After continuing to cultivate for 48 hours, add ice-cold PBS to wash 2-3 times, add 1×Binding Buffer buffer, pipette evenly, drop an appropriate amount of AV / PI mixed dye solution, incubate in the dark for 15 minutes, and use flow cytometry to detect cell apoptosis. Death.

[0031] image 3 In order to detect the experimental results of NCI-H460 cell apoptosis induced by ginsenoside Rk3 and gefitinib alone and in combination with flow cytometry, the cell histogram composed of four quadrants is obtained, and t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition for treating lung cancer. The pharmaceutical composition contains ginsenoside Rk3, gefitinib and pharmaceutically acceptable auxiliary materials. The pharmaceutical composition can remarkably inhibit lung cancer cell proliferation and growth of lung cancer nude mouse transplanted tumors, the effect is obviously better than that of the same dose of the ginsenoside Rk3 or the gefitinib which is used independently, it means that after the ginsenoside Rk3 and the gefitinib are used together, a remarkable synergistic effect is achieved, and the pharmaceutical composition is low in toxic and side effect and good in clinical application prospect.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating lung cancer and belongs to the technical field of medicines. Background technique [0002] Lung cancer is one of the most aggressive malignant tumors in the world, with the highest morbidity and mortality among malignant tumors. According to the histological classification of lung tumors proposed by the World Health Organization in 1981, lung cancer can be divided into two types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into three subtypes histologically, adenocarcinoma, squamous cell lung cancer and large cell lung cancer, which account for 80-90% of all lung cancer cases. The prognosis of lung cancer is very grim. Most lung cancer patients are already at an advanced stage when they see a doctor, and they lose the best chance of treatment. The 5-year survival rate is usually lower than 15%. [0003] The chemotherapy drug gefitinib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K31/5377A61P35/00
CPCA61K31/5377A61K31/704A61P35/00A61K2300/00
Inventor 范代娣董杨芳段志广马晓轩
Owner XIAN GIANT BIOGENE TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com